中国P站

primary bone tumors; molecular genetics; osteosarcoma; Ewing sarcoma; chondrosarcoma; oncogenic drivers; gene mutations; chromosomal translocations; tumor biology; orthopedic oncology

Introduction

Primary bone tumors are rare but clinically significant neoplasms that originate within bone tissue. They are most commonly encountered in pediatric and young adult populations, with a spectrum ranging from indolent benign tumors to aggressive malignant sarcomas. Conventional diagnosis and classification have relied on radiological findings and histopathologic evaluation [1]. However, the molecular era has introduced a paradigm shift, with genetic profiling emerging as an essential adjunct to conventional methods. Understanding the molecular and genetic characteristics of primary bone tumors not only refines diagnostic accuracy but also paves the way for targeted therapy and risk-adapted treatment strategies. This article provides a comprehensive review of key molecular features associated with major primary bone tumors, emphasizing their clinical relevance and future potential in personalized cancer care [2].

Description

Several primary bone tumors exhibit distinct genetic and molecular profiles that define their pathogenesis and clinical behavior. Among the most studied are osteosarcoma, Ewing sarcoma, and chondrosarcoma.

Osteosarcoma: This is the most common primary malignant bone tumor, typically affecting adolescents and young adults. Osteosarcoma is characterized by complex genomic instability with widespread chromosomal abnormalities [3]. Common genetic alterations include mutations in the tumor suppressor genes TP53 and RB1, as well as alterations in the PI3K/AKT/mTOR signaling pathway. Amplifications of MDM2, MYC, and CDK4 have also been observed. The heterogeneity of osteosarcoma poses significant challenges in identifying uniform therapeutic targets. Nevertheless, molecular profiling has revealed several potentially actionable mutations that are being explored in clinical trials [4].

Ewing Sarcoma: Ewing sarcoma is defined by specific chromosomal translocations, most notably the t(11;22)(q24;q12) translocation, resulting in the EWSR1-FLI1 fusion gene. This chimeric transcription factor drives oncogenic transformation by dysregulating gene expression and promoting cellular proliferation. The presence of this fusion gene is a diagnostic hallmark and has led to the development of targeted therapeutic strategies aimed at its downstream pathways, such as IGF-1R inhibitors. Other genetic events, including mutations in STAG2, TP53, and CDKN2A, have been implicated in disease progression and prognosis [5].

Chondrosarcoma: A malignant cartilage-forming tumor most frequently seen in adults, chondrosarcoma is generally resistant to conventional chemotherapy and radiation. Molecularly, mutations in isocitrate dehydrogenase genes (IDH1 and IDH2) are found in up to 60% of conventional and dedifferentiated chondrosarcomas [6]. These mutations lead to the accumulation of the oncometabolite 2-hydroxyglutarate, which contributes to epigenetic dysregulation. Other alterations include COL2A1 mutations, EXT gene deletions (in peripheral chondrosarcomas), and CDKN2A deletions. Targeted therapies against IDH mutations are currently under investigation. Beyond these three major types, other bone tumors such as giant cell tumor of bone, adamantinoma, and fibrous dysplasia have also demonstrated characteristic molecular features. For example, giant cell tumors often harbor H3F3A mutations, while adamantinomas frequently exhibit keratin expression and chromosomal imbalances [7].

Discussion

The integration of molecular and genetic findings into the clinical management of primary bone tumors offers multiple benefits:

Diagnostic Precision: Genetic markers help distinguish between morphologically similar entities. For instance, the presence of an EWSR1-FLI1 fusion confirms Ewing sarcoma, whereas H3F3A mutations support a diagnosis of giant cell tumor [8].

Prognostic Insights: Certain genetic alterations correlate with clinical outcomes. For example, TP53 mutations in osteosarcoma are associated with poor prognosis, and STAG2 loss in Ewing sarcoma may indicate increased risk of relapse.

Targeted Therapies: Identifying molecular drivers enables the development of therapies directed against specific pathways. IDH inhibitors in chondrosarcoma and IGF-1R antagonists in Ewing sarcoma represent examples of this personalized approach.

Risk Stratification: Molecular profiling allows clinicians to categorize patients into risk groups based on genetic features, enabling tailored treatment intensity. This strategy helps reduce overtreatment in low-risk patients while intensifying therapy in high-risk groups [9].

Research and Trial Design: Understanding tumor genetics facilitates biomarker-driven clinical trials and the identification of novel therapeutic targets. It also supports the design of basket trials that group patients by molecular alteration rather than tumor type. Despite these advancements, several challenges remain. The rarity and heterogeneity of bone tumors limit the availability of large, well-characterized patient cohorts for genetic analysis. Moreover, many of the mutations identified are not yet actionable with current therapies. The intratumoral heterogeneity observed in osteosarcoma complicates the interpretation of molecular data and necessitates multi-region sampling or liquid biopsy approaches to capture the full genomic landscape. Another concern is the clinical applicability of genomic data. While next-generation sequencing is increasingly available, its integration into routine practice requires standardized protocols for tissue handling, data interpretation, and clinical decision-making. Furthermore, ethical considerations around genetic testing and counseling must be addressed, particularly in pediatric and adolescent populations. Emerging technologies, such as single-cell sequencing, CRISPR gene editing, and spatial transcriptomics, are expected to further elucidate the molecular mechanisms underlying bone tumorigenesis. These tools may uncover novel biomarkers, resistance mechanisms, and therapeutic vulnerabilities that can be exploited in future treatment paradigms [10].

Conclusion

Molecular and genetic insights have profoundly enhanced our understanding of primary bone tumors, offering new avenues for diagnosis, prognostication, and treatment. As the field of orthopedic oncology evolves, the incorporation of molecular profiling into standard practice will become increasingly important. Continued research into the genetic landscape of bone tumors, coupled with advances in targeted therapy and precision medicine, holds the promise of transforming patient care. Overcoming current limitations through collaborative research, technological innovation, and integrated clinical frameworks will be essential to fully realize the potential of molecular oncology in the management of primary bone tumors.

References

1. Wilkinson TJ, Sainsbury R (1998) . Int J Aging Hum Dev 46: 333-343.

   , , Crossref

2. Gueresi P, Troiano L, Minicuci N, Bonafé M, Pini G, et al. (2003) . Exp Gerontol 38: 1189-1197.

   , , Crossref

3. Silver MH, Newell K, Brady C, Hedley-White ET, Perls TT, et al. (2002) . Psychosom Med 64: 493-501.

   , , Crossref

4. von Heideken Wågert P, Rönnmark B, Rosendahl E, Lundin-Olsson L, M C Gustavsson J, et al. (2005) . Age Ageing 34: 249-255.

   , , Crossref

5. Andersen HR, Jeune B, Nybo H, Nielsen JB, Andersen-Ranberg K, et al. (1998) . Age Ageing 27: 643-648.

   Indexed at, , Crossref

6. Palmer BW, Heaton SC, Jeste DV (1999) . Psychiatric Services 50: 1178-1183.

   , , Crossref

7. Ankri J, Poupard M (2003) . Rev Epidemiol Sante Publique 51: 349-360.

   ,

8. Miles TP, Bernard MA (1992) . J Am Geriatr Soc 40: 1047-1054.

   , , Crossref

9. Nybo H, Petersen HC, Gaist D, Jeune B, Andersen K, et al. (2003) . J Am Geriatr Soc 51: 1365-1373.

   , , Crossref

10. Stek ML, Gussekloo J, Beekman ATF, Van Tilburg W, Westendorp RGJ, et al. (2004) . J Affect Disord 78: 193-200.

    , , Crossref